Worldwide Network for Blood and Marrow Transplantation
(WBMT)
Progress Report
January-December 2014
www.wbmt.org
Headquarters: Laupenstrasse 37, Postfach 7951, CH 3001 Bern, Switzerland
WBMT Annual Progress Report
TABLE OF CONTENTS
1.0 INTRODUCTION ........................................................................................................................ 1
1.1 Early Development ............................................................................................................... 1
1.2 Working Relationship with the World Health Organization (WHO) .................................... 1
2.0 COMMITTEE STRUCTURE ......................................................................................................... 3
2.1 Board .................................................................................................................................... 3
2.2 Executive Committee ........................................................................................................... 3
2.3 Standing Committees ........................................................................................................... 3
3.0 STANDING COMMITTEE ANNUAL REPORTS AND 2014 ACCOMPLISHMENTS ......................... 5
3.1 Donor Issues Committee...................................................................................................... 5
3.2 Education and Dissemination Committee ........................................................................... 6
3.3 Graft Processing Committee ................................................................................................ 7
3.4 Transplant Center/Recipient Committee............................................................................. 8
3.5 Regulation and Accreditation Committee* (AHCTA) ........................................................... 9
4.0 WBMT ACTIVITIES AND 2014 ACCOMPLISHMENTS............................................................... 11
4.1 Annual Global Survey ......................................................................................................... 11
4.2 Scientific and Educational Conferences ............................................................................. 12
4.3 Consensus and Guideline Initiatives .................................................................................. 14
4.4 Collaboration with the WHO.............................................................................................. 15
4.5 Supporting Other HSCT Global Activities ........................................................................... 16
4.6 Website Development ....................................................................................................... 17
4.7 Research Data Task Force .................................................................................................. 17
5.0 FUTURE AIMS ......................................................................................................................... 18
6.0 PUBLICATIONS AND ABSTRACTS HISTORY ............................................................................. 19
APPENDIX A: MEMBER SOCIETIES................................................................................................ 20
APPENDIX B: EXECUTIVE COMMITTEE ELECTED OFFICERS ......................................................... 24
APPENDIX C1: CENTER SITES THAT CONTRIBUTE DATA TO THE ACTIVITY SURVEY .................... 26
APPENDIX C2: COUNTRIES THAT HAVE CONTRIBUTED DATA ..................................................... 27
APPENDIX D: HISTORY OF BOARD MEETINGS ............................................................................. 30
APPENDIX E: HISTORY OF INTERNATIONAL SCIENTIFIC SYMPOSIA ............................................. 32
APPENDIX F: PUBLICATIONS LIST ................................................................................................. 35
APPENDIX G: TERMS AND ABBREVIATIONS ................................................................................. 38
i
WBMT Annual Progress Report
1.0 INTRODUCTION
The Worldwide Network for Blood and Marrow Transplantation (WBMT) was formally created
in 2009 after two years of discussions; there was consensus on Bylaws and an organizational
structure with leaders from major hematopoietic stem cell transplantation (HSCT) and donor
registries worldwide. With the interest and support of the World Health Organization (WHO),
these leaders shared a mutual vision of combining efforts towards improving standardization in
the global application of HSCT, cellular therapy and related fields as well as broadening the
scope of data sharing. This “Federation of Societies” began with 17 international organizations
now numbering 23, all with substantial interest in HSCT (Appendix A). The WBMT was incorporated as a non-profit organization for educational, scientific, and philanthropic purposes under
the laws of Switzerland with headquarters in Bern. There is no fee for Member Societies, and its
funding support is solicited from relevant industry. Description of the first seven years of efforts
can be found in previous Progress Reports available at www.wbmt.org as they describe how
those proactive clinicians and researchers shaped the WBMT into a recognizable organization,
its structure and charter, its early achievements, and its future aims and goals. This report,
however, focuses on the accomplishments of the WBMT during the calendar year 2014.
1.1 Early Development
The four founding Member Societies of the WBMT are the Asia-Pacific Blood and Marrow
Transplantation Group (APBMT), Center for International Blood and Marrow Transplant Research (CIBMTR), European Blood and Marrow Transplantation Group (EBMT), and World Marrow Donor Association (WMDA). Representatives were invited in 2007 to help identify goals,
communicate them to all other societies with interest or stake in HSCT and related fields, and
initiate serious planning. They recognized:


HSCT is a global endeavor.
There was an urgent need to coordinate the activities of the different societies active in
this field.
 An international organization could support and even impact thoughtful, local legislation
with a global perspective.
During those early meetings, it was agreed that the WBMT required a unique organizational
structure to fulfill its goal of coordinating HSCT, stem cell donor and cellular therapy work
worldwide. It was also important that it not duplicate decades of successful efforts by other
established organizations; the result was the “Federation of Societies” structure.
1.2 Working Relationship with the World Health Organization (WHO)
The collaborative relationship with the World Health Organization (WHO) culminated in an invitation in 2012 to apply for Non-Government Organization (NGO) status; a comprehensive application was submitted, reviewed and then formally approved by the WHO Executive Committee in January 2013. It carries with it certain obligations affecting WBMT activities (Section
4.4).
1
WBMT Annual Progress Report
As noted above, the WHO strongly supported the early collaborative and unifying efforts and
representatives continue to attend meetings as “observers”, assist in planning activities, and
participate as forum presenters on a variety of relevant topics. Since acquiring NGO status,
WBMT is obliged to provide a set of deliverables to the WHO in constant pursuit of its educational, scientific, and philanthropic mission; see Section 4.4.
2
WBMT Annual Progress Report
2.0 COMMITTEE STRUCTURE
2.1 Board
The Board is the highest tier of decision making for all WBMT activities. The WBMT Board includes elected Executive Committee officials (President, Vice-President, Secretary and Treasurer and President-elect and/or Immediate Past President) as well as a primary and alternate representative from each of the twenty-three Member Societies. Each Member Society is permitted a single vote, either by the primary or the alternate representative. The Board also includes
co-Chairs of the Standing Committees (see below) who, since Bylaw changes approved during
2014, also have voting privileges.
The Board meets annually in person (alternating between the winter BMT Tandem Meetings in
the U.S. and the spring EBMT meetings in Europe) and holds two teleconferences, in summer
and late fall, to handle issues between the in-person sessions. Meeting minutes are posted on a
password-protected section of the website (www.wbmt.org).
2.2 Executive Committee
The Executive Committee advises the Board and manages all business matters between Board
meetings. Membership includes the elected President, Vice-President, Treasurer, Secretariat ,
and President-Elect and/or Immediate Past President. Additionally, appointed Chairs of the six
Standing Committees (Sections 2.3 and 3.0) serve on the Executive Committee. The Executive
Committee conducts monthly hour-long teleconferences and minutes of these meetings are
also posted on a password-protected section of the website.
Following Nomination and Election House Rules that were updated in 2013, and with input
from Board members, an ad hoc Nominating Committee, including one representative from
each WHO region, also convenes as necessary. There were no nomination/election activities in
2014. Appendix B displays photos and contact information for all current, elected Executive
Committee members.
2.3 Standing Committees
Six Standing Committees focus on areas of prime importance to the mission of the WBMT, as
identified by the Executive Committee. Most of these committees were created in 2008, and
co-Chairs were appointed at that time. These appointed positions were reviewed during 2014;
only minor changes were made in committee leadership positions. The majority of WBMT project work is accomplished by these Standing Committees:






Donor Issues
Education and Dissemination of Information
Graft Processing
Nuclear Accident Committee (NAC)
Transplant Center/Recipient Issues
Regulation/Accreditation [the international Alliance for Harmonization of Cellular
Therapy Accreditation (AHCTA) serves in this capacity]
3
WBMT Annual Progress Report
Two or three co-Chairs lead each committee. These co-Chairs also participate in the ongoing
work and decisions of the Executive Committee as noted above. Any interested individual belonging to any one (or more) of the Member Societies is eligible to join these committees;
membership is solicited periodically.
In late 2013 the Board approved development of the newest Standing Committee, the Nuclear
Accident Committee. Implementation of such a committee within WBMT remains a work in
progress; it is led by individuals from the APBMT, the EBMT and the U.S. based Radiation Injury
Treatment Network (RITN).
Because the committees are project driven, they meet with varying frequency, usually by teleconference. They also take advantage of related international meetings attended by many of
their members for in-person dialog.
4
WBMT Annual Progress Report
3.0 STANDING COMMITTEE ANNUAL REPORTS AND 2014 ACCOMPLISHMENTS
3.1 Donor Issues Committee
Committee Mission:
The mission of the Donor Issues Committee is to recommend to the Executive Committee policies, programs, and actions in the area of any/all issues pertaining to the identification of stem
cell donors [bone marrow (BM), peripheral blood (PB) and cord blood (CB)], harvesting procedures, product transportation, donor safety practices, and outcomes/long term follow-up within a member collection center; this includes the conduct of individuals and processes related to
these procedures and practices.
Leadership:
The co-Chairs of this Standing Committee are:


Jorge Halter (Member Society, EBMT)
Vanderson Rocha (Member Society, WMDA)
Meetings/Teleconferences:
This Standing Committee met in person on March 31, 2014 in Milan, Italy. There were no
scheduled teleconferences.
Completed Projects:
During 2014, this Standing Committee completed the following projects:


Three papers on suitability criteria for donors with non-infectious health disorders were
submitted recently (Appendix F);
Speaker, Chair, and planning contribution to the 2014 Workshop in South Africa.
Ongoing Projects:
This Standing Committee continues to work on the following projects:


Development of donor eligibility criteria for pediatric or elderly donors and donors with
comorbidities. The broad project aims to provide recommendations on donor eligibility
criteria for donors who would not qualify as healthy volunteer unrelated donors.
Leadership: WBMT Standing Committee on Donor Issues. [Note: this initiative was on
the program of a September 2013 Donor Outcome Workshop in Vienna (local
organizers: Medical University Vienna, Austrian Registry for unrelated hematopoietic
stem cell donors). Additional papers on pediatric donor issues and donors with
infectious health disorders are in preparation.
Initiation of a global survey on the use of cord blood grafts. The project aims to
understand the use of cord blood grafts and exchange of cord blood grafts among
different countries, cord blood banks and donor registries. This project involves many
participants of WBMT, such as Eurocord, EBMT, WMDA, NMDP, CIBMTR, etc.; the
targeted date of completion is 2014/2015.
5
WBMT Annual Progress Report
Future Plans:
This Standing Committee has identified the following projects for initiation during 2015:


Preparing for a 4th Donor Outcome Workshop in 2015;
Authoring recommendations for cord blood graft selection.
Publication:
Several papers were submitted in 2014 (see above and Appendix F).
3.2 Education and Dissemination Committee
Committee Mission:
The mission of the Education and Dissemination Committee is to recommend to the Executive
Committee policies, programs, actions and materials pertaining to the development or design
of resources prepared for the express purpose of educating a populace about HSCT. This committee collaborates with all partners within the WBMT - but particularly the ESH - and assists in
“single voice” preparation of opinion or advisory materials for the WBMT and/or WHO. It plays
an important role in Workshop program design.
Leadership:
The Chair of this Standing Committee is:

Eliane Gluckman (European School of Hematology, ESH and Eurocord)
Meetings/Teleconferences:
This Standing Committee met in person on March 31, 2014 in Milan, Italy.
Completed Projects:
During 2014, this Standing Committee completed the following projects:





Publication on line of the 6th Edition of the ESH-EBMT handbook on hematopoietic stem
cell transplantation;
Translation of the ESH-EBMT Handbook into Spanish and Portuguese with Drs. Adriana
Seber and Belinda Simoes (in collaboration with the Brazilian Society of Hematology);
ESH-EBMT training course in Vienna, May 2014;
Organisation of the World Cord Blood Congress V in Monaco, March 2015;
Speaker, Chair, and planning contribution to the 2014 Workshop in South Africa.
Ongoing Projects:
This Standing Committee continues to work on the following projects:


Translation of the ESH-EBMT Handbook into Portuguese with the help of the Brazilian
Society of Hematology;
Organization of an ESH-EBMT HSCT training course in Malaga, Spain in May 2015;


Educational book on bone marrow failure syndromes;
Educational book on hemoglobinopathies.
6
WBMT Annual Progress Report
Future Plans:
This Standing Committee has identified the following projects for initiation during 2015:



Developing new educational tools (e.g., e-learning program, webinar conferences);
Developing online training programs;
Participating in the creation of an International Continuing Medical Education (CME) accreditation plan.
Publications:
There were none in 2014.
3.3 Graft Processing Committee
Committee Mission:
The mission of the Graft Processing Committee is to recommend to the Executive Committee
policies, programs, and actions in the area of any/all issues pertaining to the handling of a harvested product: storage, preparation and manipulation equipment, product transportation
practices, and documentation within a member cell processing center; this includes the conduct
of individuals and processes related to these procedures and practices.
Leadership:
The co-Chairs of this Standing Committee are:


Mickey Koh (Member Society, International Sociey of Blood Transfusion, ISBT)
Carolyn Taylor [Member Society, Foundation for the Accreditation of Cellular Therapy,
(FACT)]
Meetings/Teleconferences:
This Standing Committee met in-person in Milan (April 2014) and co-Chairs and committee representatives attended the ISCT meeting in Paris (May 2014). There was a joint call with the ISCT
group regarding the Cellular Tourism project on October 2, 2014 and a committee teleconference conducted on October 17, 2014.
Completed Projects:
During 2014, this Standing Committee participated in the following projects:


Expertise and technical assistance provided (with Dr. David Ma; APBMT) on the setting
up of an autologous transplant programme in Myanmar; subsequently successfully
transplanted one patient with myeloma;
Speaker, Chair, and planning contribution to the 2014 Workshop in South Africa.
Ongoing Projects:
This Standing Committee continues to work on the following projects:


Continuing updates to FAQs document: Project Leader, Carolyn Taylor;
Collaborating with ISCT on the issue of Cell Therapy Medical Tourism in hopes of presenting this important topic to the WHO General Assembly in 2015;
7
WBMT Annual Progress Report

Continuing representation of WBMT in the WHO initiative on Medical Products of
Human Origin (MPHO; see Section 4.4).
Future Plans:
This Standing Committee has identified the following projects to initiate during 2015:




Creating a map of Cell Processing laboratory facilities worldwide;
Collaborating with ISCT on the issue of Cell Therapy Medical Tourism in hopes of presenting this important topic to the WHO General Assembly;
Collating the differing practises for cryopreservation worldwide focusing on methodologies which are not dependent on the availability of controlled rate freezing;
Working with the EBMT Cellular Therapies Working Party.
Publication:
The following manuscript was the result of the efforts of this Standing Committee:

Minimal Requirements and Essential Features for Setting up a Stem Cell Processing Laboratory: Leemhuis T, Padley D, Keever-Taylor C, Teshima T, Lanza F, Chabannon C, Szabolic P, Bazarbachi A, Koh M; on behalf of the Graft Processing Subcommittee of the
Worldwide Network for Blood and Bone Marrow Transplantation (WBMT). Bone Marrow Transplantation 2014 Aug; 49 (8):1098-105 (see Appendix F).
3.4 Transplant Center/Recipient Committee
Committee Mission:
The mission of the Transplant Center/Recipient Committee is to recommend to the Executive
Committee policies, programs, or actions in the area of any/all recipient issues pertaining to the
performance of hematologic transplantation and other cellular therapies/procedures within a
member transplant center; this includes recording recipient outcomes, maintenance of records
and the conduct of individuals and processes carrying out these procedures and practices. Effective in 2014, this committee will also administer all activities related to the global transplant
activity reports and data use proposal reviews.
Leadership:
The co-Chairs of this Standing Committee are:


Marcelo Pasquini (Member Society, CIBMTR)
Jane Apperley (Member Society, JACIE)
Meetings/Teleconferences:
This Standing Committee did not meet in person during 2014, but the two co-Chairs met extensively while in Milan, Italy. Due to their lead role in the Research Task Force (see section 4.7),
there were 2 teleconferences related to this project in 2014.
Completed Projects:
During 2014, this Standing Committee completed the following projects:
8
WBMT Annual Progress Report


Draft preparation of the Research Guidelines document (see section 4.7)
Speaker, Chair, and planning contribution to 2014 Workshop in South Africa.
Ongoing Projects:
This Standing Committee continues to work on the following projects:


Recommending “Minimal requirements” for reporting data to a registry; implemented
by APBMT participating centers in 2012;
Providing leadership for the Research Data Activities Task Force and designing the format/structure for presentation of a series of transplant center global survey reports indicating volume data, center information and trends. These will be made available to all
Member Societies.
Future Plans:
This Standing Committee has identified the following projects to initiate during 2014:



Completing a “Minimal Requirements” document for transplant centers and submit for
publication.
Initiating a transplant cost initiative as an exploratory project on costs and charges of
transplant around the world. This would include a comparison of transplant cost (in any
country or region regardless of development level) versus non-transplant therapies for
certain indications. An end product will be publication of this scientific report.
Developing an annual report from the Global Transplant Activity in a form of a slide set
to be available to all member societies in the WBMT website
Publication:
During 2014, the following manuscript was the result of the efforts of this committee:

Challenges and Opportunities for HSCT Outcome Registries; Perspective from International HSCT Registries Experts: Aljurf M, Rizzo J D, Mohty M, Hussain F, Madrigal A, Pasquini MC, Passweg J, Chaudhri N, Ghavamzadeh A, El Solh H, Atsuta Y, Szer J, Kodera Y,
Niederweiser D, Gratwohl A, Horowitz MM. Submitted to BMT in late 2013 and published as a Special Report during 2014 (see Appendix F for full citation).
3.5 Regulation and Accreditation Committee* (AHCTA)
*(managed by the Association for the Harmonization of Cellular Therapy Accreditation; AHCTA)
Committee Mission:
The mission of the Regulation and Accreditation Committee is to recommend to the Executive
Committee policies, programs, and actions in the area of any/all issues pertaining to regulatory
matters, practices and codes with both inter- and intra-national implications. This involves procedures related to all activities of the other five Standing Committees. In its vigilance to avoid
duplication of efforts, WBMT members agreed early (2009) that AHCTA shall fulfill the role of
the WBMT Regulation and Accreditation Committee.
9
WBMT Annual Progress Report
Leadership:
The Chair of this Standing Committee is:

Kathy Loper (Member Society, AABB)
Meetings/Teleconferences:
The committee generally meets by teleconference once per month (the first Wednesday of the
month) and in person once or twice per year, as international conference attendance permits.
During 2014, this Standing Committee met twice in person and held ten committee calls as well
as several project team calls.
Completed Projects:
During 2014, this Standing Committee completed the following projects:





Publication of a paper on cell collection staff training (see below and Appendix F);
Launch of a survey of training practices for human progenitor cell (HPC) and bone
marrow collection and accumulated results. Analysis is ongoing and publication
planned;
Resource update on website, www.ahcta.org;
Launched a LinkedIn group for AHCTA (late 2014);
Speaker, Chair, and planning contribution to the 2014 Workshop in South Africa.
Ongoing Projects:
This Standing Committee continues to work on the following projects:


Completing the training practices survey for laboratory staff. Once completed, the
recommendations will be submitted for publication. Project Leads: C Keever-Taylor;
I Cortenbach-Slaper.
Collaborating with and support of LABMT by assisting with webinars and educational
program development.
Future Plans:
This Standing Committee hopes to identify, during 2015, new projects that would serve the
HSCT community and align with the mission of AHCTA and WBMT.
Publication:
The following paper was first submitted to Transfusion in December 2013, accepted in spring
2014 and published in December 2014; see Appendix F for full citation.

Training Practices of HPC(A) and HPC(CB) Collection Staff: Analysis of a Survey by the Alliance for Harmonisation of Cellular Therapy Accreditation; Celluzzi CM, Keever-Taylor C,
Alurf M, Koh K, Rabe F, Rebulla P, Sacchi N, Sanders J, McGrath E, Loper, K on behalf of
The Alliance for Harmonisation of Cellular Therapy Accreditation (AHCTA).
10
WBMT Annual Progress Report
4.0 WBMT ACTIVITIES AND 2014 ACCOMPLISHMENTS
The WBMT engages in a variety of activities including:







Generating an annual global survey of HSCT activity;
Conducting scientific and educational conferences;
Developing consensus guidelines for optimum delivery of HSCT services and
accreditation of HSCT facilities;
Collaborating and consulting with the WHO to promote excellence in HSCT, stem cell
donation and cellular therapy;
Supporting other global HSCT activities;
Developing a Website for broad communication;
Establishing research guidelines within this global HSCT community.
4.1 Annual Global Survey
WBMT leaders agreed in early formative years that a first initiative should be to conduct annual
global surveys of activity performed by transplant centers (Appendices C1 and C2); a minimal
yet essential level of activity information is requested of participating centers. The annual survey displays volume of, and main indications for, allogeneic and autologous HSCT activity. These
data were previously unknown, and centers were not represented on a map. WBMT needed
these baseline data to support future projects and assist countries in increasing their activity
levels and/or in the development of new transplant programs.
The WBMT survey reporting sheet is available on the website (http://www.wbmt.org/en/
wbmt-survey), along with disease indications for HSCT and accompanying main- and sub-class
codes for use in completing the survey. WBMT continues to promote the annual survey by publishing findings biannually and presenting results periodically at international meetings (Appendix E); data are presented internationally at least once annually. WBMT also encourages other,
newer groups forming their own registries to participate in the survey [e.g., Latin American
Blood and Marrow Transplant Society (LABMT), African Blood and Marrow Transplant group
(AFBMT)]. These data are also provided to the Global Observatory for Donation and Transplantation (Section 4.1.2).
A new tool (Transplant Activity Survey; TAS) was designed for the WBMT Activity Survey that
allows the reporting of transplant activity via the web using a simple, user-friendly input form
that is similar to the reports (easy, single page record) already being provided to WBMT via a
regional transplant society, national Registry or by individuals at the team/center level – and
mathematical calculations are performed automatically avoiding human error. Activity data
can still be entered at either the country or center level.
These data do not represent an outcome registry, but the TAS is a mechanism by which each
country’s annual data can be registered to the WBMT (in the format of the survey sheet that
WBMT has used historically) and put to further use within the reporting organization.
These data are used in the following ways.
11
WBMT Annual Progress Report
4.1.1 Team access
These activity data can be used at the team level for those countries/societies (e.g. LABMT, AFBMT) that do not have an existing data collection system.
If an outcome registry were to be developed, it could potentially use the TAS to identify the
activity in those countries that are outside other data collection systems (e.g., CIBMTR, EBMT,
etc.), providing a mechanism for follow-up. An idea was presented recently suggesting that outcome data reported to the CIBMTR could be provided back to new reporting teams in the future via its “Data Back to Center” Program. This project remains a work in progress.
4.1.2 Organización Nacional de Transplantes, ONT
Data on international use of HSCT are gathered inconsistently across the globe but usually by
registries and professional societies. The Department of Essential Health Technologies of the
WHO and the Spanish National Transplant Organization (Organización Nacional de Transplantes, ONT) established the Global Observatory on Donation and Transplantation beginning in
2007. These collaborative activities help to meet the requirements of the 57th World Health
Assembly Resolution WHA57.18. This resolution suggests that the collection of global data on
the practices, safety, quality, efficacy and epidemiology of transplantations, their global availability for all those concerned, including professionals, patients, politicians and the general public, are all recognized as a prerequisite for global improvement of, and better access to, transplantations [(Organs, Tissues and Cells, (2), 91-94, 2007].
One goal of the Observatory is the development of a global database on donation and transplantation. WBMT Member Societies, particularly the WMDA and Bone Marrow Donors
Worldwide (BMDW), contributed substantially by providing unrelated donor information from
their own databases to this Observatory databank. WBMT provided its first activity contribution
to the Global Observatory in 2012 with Global Survey data from 2006-2008, and now updates
these data as they become available. The 2009-2010 data were provided by WBMT in April
2014.
4.2 Scientific and Educational Conferences
4.2.1 Joint Scientific/International Symposia
Scientific conferences are an important activity of the WBMT for communicating with other
clinicians and researchers. WBMT conducts an annual 90 minute Scientific/International Symposium first presented during the U.S.-based CIBMTR BMT Tandem Meetings (co-sponsored
with the American Society for Blood and Marrow Transplantation, ASBMT) each February, and
then essentially repeated during the annual EBMT meeting in spring. These meetings represent
the premier gathering in the U.S. and in Europe for clinicians and researchers interested in
HSCT. The focus is similar for each of the two WBMT Symposia with the same topics, but occasionally with different expert speakers due to logistical considerations. See Appendix E for a list
of annual Symposia programs since WBMT began coordinating them in 2009.
Planning for these 2015 sessions occurred during late 2014.
12
WBMT Annual Progress Report
4.2.2 WBMT Workshops
The WBMT also sponsors Workshops in regions with constrained resources, a demonstrated
need and interest, and clinicians who wish to expand existing transplant programs or to start a
new program. These activities are aimed at regions where resources and unique factors present
challenges to clinicians wanting to provide easier access to their peoples in need of this modality. The WBMT leverages the skills and expertise of its Education and Dissemination Standing
Committee and the European School of Haematology (ESH, a WBMT Member Society) along
with all other Standing Committees, in planning these programs.
A first two-day Workshop (and associated one-day Scientific Symposium) was conducted in Hanoi, Vietnam, in late 2011, in cooperation with the WHO and in partnerships with the APBMT
and a local Vietnamese Organizing Committee. A descriptive manuscript is near completion for
submission to two peer-reviewed journals: Blood and Marrow Transplantation and Biology of
Blood and Marrow Transplantation.
One important result of the Hanoi Workshop was the suggestion that WBMT conduct training
programs for physicians who lead transplant programs abroad. Since then, several teaching
fellowships materialized during 2013 and 2014 including practitioners from Vietnam (Hanoi and
Ho-Chi-Minh), Mongolia, Qatar, the Philippines and Cambodia cross-training in Japan, Korea,
Belgium or Germany. Another positive outcome of this Workshop was the networking opportunity that resulted in Myanmar and Bangladesh representatives establishing an HSCT program
under the guidance of WBMT members who participated in the 2011 Workshop.
4.2.2.1 2013 Brazilian Experience
With these successes in mind, and a commitment by the WBMT Board to support the Latin
American Blood and Marrow Transplantation Society (LABMT, a new WBMT Member Society
since 2013), a local organizing committee indicated strong interest in co-hosting a Workshop
with a Program similar to that conducted in Hanoi. After many months of planning a second 2day Workshop (and 1-day Scientific Symposium) convened in late 2013 in Salvador-Bahia, Brazil.
Indications onsite and since are that participants thought this was a successful and valuable
collaborative venture, but the most visible measurement of success is the high level of organization and productivity since the Workshop, resulting from the active output of the LABMT.
There are regular monthly and annual meetings, all standing committees (modelled after
WBMT committees) are very actively fulfilling missions, and, not only have there been publications in peer-reviewed journals, but an LABMT abstract was accepted for oral presentation during the 2014 American Society of Hematology (ASH) meetings. These are achievements of a
group that admitted during the 2013 Workshop that they had never met before an integrated
group. Also important were the contributions of several LABMT members in the planning and
production of the 2014 Workshop held in Cape Town, South Africa.
4.2.2.2 2014 South African Experience
Cape Town, South Africa was the site of the 3rd WBMT Workshop again convened in collaboration with the WHO and a local, South African planning committee. These sessions occurred on
November 14, 15 and 16, 2014. They were attended by the largest audience yet including representatives of 34 countries, 20 of which were African. There were 212 registrants though not
13
WBMT Annual Progress Report
all were able to attend and for the first time Workshop evaluations were distributed onsite with
a 44.8+% return; these are not yet fully assessed but contain primarily positive responses and
comments. The scientific Program was customized to address blood transfusion safety - a special problem on the continent - and logistically included far more open dialog time than in previous Workshop programs. A strong emphasis was placed on the value of activity reporting and
formation of local databases. It is hoped that an increase in reporting to the WBMT from the
African continent will be a measurable outcome of this 3 rd Workshop.
As was true both in 2011 and 2013, a broad spectrum of expert planners and presenters were
from Europe, the Far East, Mediterranean region, and the U.S., augmenting a cadre of regional
speakers. Programs for all three Workshops are available at www.wbmt.org.
As was true after the Brazilian Workshop, WBMT encourages and strongly supports a more
formal structure and activity level of an African Blood and Marrow Transplantation group (AFBMT). It met first in Lagos, Nigeria in 2011 and an application for status as a WBMT Member
Society is expected in early 2015.
Already there are preliminary discussions about a 4th WBMT Workshop. The idea for future
Workshops is to focus more on smaller regions (vs entire continents) with an aim to assist in
expansion and improvement of existing Programs.
4.2.3 Donor Outcome Workshop 2013
The WBMT Donor Issues Standing Committee, having sponsored three successful Donor Outcome Workshops previously (in 2009, 2011 and in 2013) anticipates a 4th session during 2015;
plans are in progress. Recommendations on suitability criteria for donors with non-infectious
health disorders as well as donors with comorbidities were topics in the past resulting in manuscripts submitted for publication (See Appendix F, 2014). Previous accomplishments of this
committee, as a result of these Workshops, include generation of several publications describing recommendations for minimal datasets for collecting donor data and assessing donor outcomes.
4.3 Consensus and Guideline Initiatives
The primary purpose of the WBMT is to serve as a single voice – at a global level – for HSCT and
related issues. With the support of its Board, WBMT publicizes its sentiments on controversial
or critical matters on its website and/or collaborates with other likeminded groups in opinion
solidarity. Previously this included WBMT positions on support of standardized product labelling and rejection of financial reimbursement for donation of cellular products; details can be
seen in previous Progress Reports and formal statements are available at http://wbmt.org/ and,
regarding reimbursement for donors, also at:
http://marrow.org/News/News_Releases/2012/Coalition_says_PBSC_donor compensation_poses_health_risks_to_patients_and_donors.aspx.
More recently, some Standing Committees have authored substantial works, either independently or collaboratively, on standardization of practice topics (e.g., minimal requirements,
etc.) associated with respective committee mandates (Section 3.0 and Appendix F).
14
WBMT Annual Progress Report
4.4 Collaboration with the WHO
As noted previously, a WHO representative has been involved with WBMT activities since the
earliest concept development meetings. WBMT maintained a “working relationship” with the
WHO for almost four years thereafter when, meeting important criteria, it was officially invited
to apply for NGO status. NGO status provides WBMT with the opportunity to continue its work
on a more formal basis in partnership with the WHO in promoting excellence in HSCT, stem cell
donation, and cellular therapy. These efforts all came to fruition with the January 2013 NGO
status approval which, as implied above, brings with it partnership demands and participation
in other WHO initiatives in pursuit of mutual educational, scientific, and philanthropic missions.
An example of a WHO initiative in which WBMT representatives participate is the ongoing NOTIFY Project having attended a first meeting in Bologna in 2011 and remaining involved through
the group’s last meeting in December 2013 in Brasilia, Brazil. One sub-project of the broader
NOTIFY Project is referred to as BIG V&S (Bologna Initiative for Global Vigilance and Surveillance), coordinated by the WHO and the Italian National Transplant Centre (CNT) in further collaboration with the SOHO V&S (Vigilance and Surveillance of Substances of Human Origin) project.
An important accomplishment of the NOTIFY group of experts was the development of the
NOTIFY Library – a large database launched in December 2013 for access to global data revealing instances of adverse outcomes. WBMT was in a unique position to make important recommendations to this group in Brasilia, including suggestions regarding changes in cell type taxonomy data items and better use of keywords specifically related to cellular therapies contained
within. WBMT representatives also recommended that an editorial board be formed including
more specialists in hematopoietic progenitor cell therapies and to improve website navigation
processes, etc. The experts in this “Blood Working Group” will eventually join existing editorial
working groups and, as the work develops, an Editorial Group will be established for Transfusion Reactions. Though planned for 2014, an in-person meeting had to be cancelled.
During 2014 there were two more initiatives in which WBMT representatives were very involved in partnership with the WHO. WBMT is one of four WHO NGOs assigned to the Medical
Products of Human Origin (MPHO) project. An international guidelines document, largely focused on donor concerns, is currently under circulation amongst the four participating NGOs.
The aim is to present the document to the WHO Executive Committee in late January 2015 for
final approval and implementation.
The other initiative in which WBMT members have been more actively involved during 2014 is
that of cellular therapy tourism – most importantly, the risks involved particularly to recipients.
The International Society of Cellular Therapy (ISCT, a WBMT Member Society) took first lead
and collaborated with others in preparing a statement warning the public of considerations
when going abroad seeking cellular therapy of one kind or another for a medical problem.
WBMT was invited to participate in the project and representatives recently contributed to a
revised guidelines document which is also now under review for broader circulation.
15
WBMT Annual Progress Report
A report on both of these last two initiatives is scheduled for presentation by the WBMT WHO
observer/partner during the 2015 WBMT Scientific International Symposium at both the BMT
Tandem Meetings and EBMT meetings.
The 2012 NGO application process distinguished those collaborative projects already in progress (or completed) at the time , versus those projected for the subsequent three-year period
(should WBMT be approved as an NGO partner). With the award of official NGO partnership
status in 2013, WBMT is now obligated to continue its work on specific identified projects at
least through early 2016 when the WHO reviews WBMT accomplishments and approves maintaining the relationship.
Those activities in progress or already completed in 2012 were:




Collect and share data (Section 4.1 and 4.1.2);
Conduct Workshops (Section 4.2.2, 4.2.3);
Provide technical and scientific support (Section 4.1, 4.2, 4.3 and 4.4);
Foster and shepherd development of regional HSCT societies (Section 4.5).
Those activities to which WBMT committed in its NGO application (and were subsequently approved) are:








Work with the Global Observatory on Donation and Transplantation (Section 4.1.2);
Promotion of access to HSCT – stem cell donation (Section 4.2);
Develop a Donation Guidance Document (Section 4.2.3);
Promotion of access to HSCT – stem cell transplantation (Section 4.2, 4.3 and 4.5);
Technical and Scientific Input on Safety and Quality of HSCT (Section 4.2 and 4.3);
Global Consultation on Ethics, Safety and Access to HSCT (Section 4.2, 4.3 and 4.4);
Initiative for Global Vigilance and Surveillance of Adverse Reactions and Events (Section
4.4);
Consultation Services (Section 4.0; ad hoc).
These final eight specific activities form the foundation for the continued work of the WBMT.
4.5 Supporting Other HSCT Global Activities
In addition to the above, WBMT has been instrumental in supporting the now highly successful
development of the new LABMT. The LABMT first met in 2010 and approved an interim Board;
they passed bylaws in December 2012. The full group met during the 2013 BMT Tandem Meetings in Salt Lake City; its application for formal WBMT Member Society status was approved by
the WBMT Board in February 2013. During the October 2013 Workshop, the group conducted a
business meeting during which an Executive Committee was elected; the committee has been
meeting regularly since.
Similarly, in November 2011, the WBMT became involved in supporting establishment of an
African Blood and Marrow Transplant Group (AFBMT) when invited to attend a meeting in Nigeria which included South African representatives as well. They are of similar mind to form an
expended African group of HSCT clinicians. A small, interim Executive Committee now exists to
begin the building process; a leader is in place and WBMT awaits their formal application for
16
WBMT Annual Progress Report
Member Society status. The WBMT places high focus on the AFBMT as it represents the single
remaining continent that has not uniformly reported transplant activity or outcome data.
Both groups have been encouraged to commit to participate in the annual WBMT global activity
survey noted above (section 4.1). A positive outcome of the Workshop in Latin America is the
numerous new transplant centers providing activity data to this survey. The same consequence
is anticipated as a result of the just completed 2014 Workshop in Africa as several participants
indicated on evaluations a willingness to begin reporting HSCT activity data. This is an important
step forward in addressing the current gap in acquisition of data from these regions.
4.6 Website Development
The WBMT website, launched in 2010, is hosted and serviced in Bern, Switzerland, by the Swiss
Blood Stem Cells group. Identifying itself via the internet was an important first step in the evolution of the WBMT. Substantial effort is placed continually into posting current documents
such as meeting minutes and Workshop/Symposium Programs as well as important newsworthy items (e.g., approved NGO status with the WHO, one millionth transplant announcement in
early 2013, consensus statements, etc.).
During 2014, the website was particularly effective in dissemination of the Workshop and Scientific Symposium notices and programs as well as registration processes. Further attention
was paid this past year to making available starter pages for notices and meeting documents for
the LABMT and AFBMT.
4.7 Research Data Task Force
In Salt Lake City in 2013, the WBMT Board mandated development of a Task Force for the purpose of developing guidelines for management and use of the WBMT Global Activity data as
well as guidelines for how general research should be managed in collaboration amongst
WBMT Member Societies. There were numerous teleconferences and then a report to the
Board in December 2014 during which the Board approved an important recommendation that
the Transplant Center and Recipient Standing Committee (see Section 3.4) administer all activities related to the global transplant activity survey, reports and proposal reviews. The guidelines document revisions are almost complete and the Task Force will present to the Board a
final time in February 2015. Once completely approved, the document will be posted on the
WBMT website.
17
WBMT Annual Progress Report
5.0 FUTURE AIMS
WBMT continues to evolve, and though it has identified many activities with which it wants or
needs to be involved, limited resources and availability of this volunteer group of leaders and
committee members affect the selection of projects for its portfolio. In addition to the plans
identified in Section 3.0 by each of the Standing Committees, the Executive Committee is assessing priority activities for 2015 and beyond. They are to:











Establish a more durable mechanism for soliciting and sustaining high level financial
support.
Continue close collaboration with the WHO on global projects relevant to HSCT and
fulfilling WBMT responsibilities as an NGO.
o Complete work on the Medical Products of Human Origin (MPHO) project.
o Continue collaboration on the cellular tourism project with the ISCT and other
WBMT Member Societies.
Complete the Hanoi Workshop manuscript.
o Publish an algorithm for establishing a new HSCT program as identified during
the Hanoi Workshop.
Complete the Salvador Workshop report, and begin drafting its manuscript.
Complete the Africa Workshop report and begin drafting its manuscript.
o Continue efforts in support of an AFBMT.
Consider a 4th Workshop and Scientific Symposium.
o Adjust the approach from continental to regional.
Continue the mission of the Reserach Data Task Force for identification of proper
procedures for research coordinated by the WBMT.
Establish a fully operational, global level, Nuclear Accident Standing Committee in
collaboration with existing nuclear accident committees to extend the concept of
“speaking with one voice”.
Continue developing the concept of a related donor registry in association with the
Donor Issues Committee’s long term agenda.
Continue support of transplant center twinnings and/or cross-training activities.
Continue efforts towards establishing a unique Global Transplant Center Number
(GTCN) to improve data sharing capabilities at a global level.
18
WBMT Annual Progress Report
6.0 PUBLICATIONS AND ABSTRACTS HISTORY
Some works are published on behalf of WBMT whereas others are credited to a WBMT Standing Committee. Appendix F displays the complete WBMT publication portfolio while identifying
which entity is credited; it includes those manuscripts submitted during 2014 but remaining
under review.
A WBMT abstract history since inception is as follows:
The following abstract was submitted on behalf of the WBMT and accepted for poster
presentation at the American Society of Hematology (ASH) meetings in December 2013:

Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement
Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The
Worldwide Network For Blood and Marrow Transplantation (WBMT). Dietger Niederwieser, MD, Marcelo C Pasquini, MD, MS, Mahmoud D. Aljurf, MD, Dennis L. Confer,
MD, Helen Baldomero, Luis Fernando Bouzas Sr., MD, MSC, PhD, Mary M. Horowitz,
MD, MS, Minako Iida, MD, Yoshihisa Kodera MD, PhD, Jeffrey H. Lipton, MD, PhD,
Machteld Oudshoorn, Eliane Gluckman, MD, Jakob R. Passweg, MD, Jeffrey Szer, MD,
Nicolas Novitzky, MD, PhD, Jon J. van Rood, MD, Luc Noel, MD, J. Alejandro Madrigal,
MD, PhD, Karl Frauendorfer, Alois Gratwohl, MD and Frederick R. Appelbaum, MD
The following abstract was presented as a poster on behalf of the WBMT at the ASH meetings
in December 2012:

Clinical Allogeneic and Autologous Transplantation - Results: Poster II Global Trends in
Hematopoietic Cell Transplantation. Helen Baldomero, Mahmoud Aljurf, MD, Luis
Fernando Bouzas, MD, MSC, Alois Gratwohl, MD, Yoshihisa Kodera, MD, PhD, Jeff H
Lipton, MD, J. Alejandro Madrigal, MD, PhD, Iida Minako, MD, Nicolas Novitzky, MD,
PhD, Marcelo C Pasquini, MD, MS, Jakob R. Passweg, MD, Adriana Seber, MD, Jeffrey
Szer, MBBS and Dietger Niederwieser, MD
The following abstract was presented orally on behalf of the WBMT at the ASH meetings in December 2011:
Global use and trends in hematopoietic stem cell transplantation: A targeted approach for a
widening gap. Dietger Niederwieser, MD, Helen Baldomero, Michael Gratwohl, Mahmoud
Aljurf, MD, Luis Fernando Bouzas, MD, MSC, Mary Horowitz, MD, MS, Yoshihisa Kodera, MD,
PhD, Jeff Lipton, MD, PhD, Iida Minako, MD, Marcelo C. Pasquini, MD, MS, Jakob Passweg, MD,
Jeff Szer, MD, Alois Gratwohl, MD, Karl Frauendorfer for the Worldwide Network of Blood and
Marrow Transplantation.
For more information about items included in this report, please contact any WBMT Officer
(Appendix C).
19
WBMT Annual Progress Report
APPENDIX A: MEMBER SOCIETIES
Organization
AABB
www.aabb.org
American Society for Histocompatibility and Immunogenetics (ASHI)
www.ashi-hla.org
American Society of Blood and
Marrow Transplantation (ASBMT)
www.asbmt.org
Asia Pacific Blood and Marrow
Transplantation (APBMT)
www.apbmt.org
Australasian Bone Marrow Transplant Recipient Registry (ABMTRR)
www.abmtrr.org
Bone Marrow Donors Worldwide
(BMDW)
www.bmdw.org
Center for International Blood and
Marrow Transplant Research
(CIBMTR)
www.cibmtr.org
Description
AABB, formerly known as the American Association of
Blood Banks, is an international non-profit association
committed to advancing the practice and standards of
transfusion medicine and cellular therapies to optimize
patient and donor care and safety.
ASHI is a non-profit association of clinical and research
professionals that is dedicated to advancing the science
and application of histocompatibility and immunogenetics as well as advocating the highest standards of laboratory testing in the interest of optimal patient care.
ASBMT is an international association that promotes the
advancement of the HSCT field by representing the interests of transplant clinicians and investigators as well
as the patients they serve.
A Founding Member: APBMT is an international organization of HSCT researchers that allows physicians in
Asian countries involved in HSCT to share their experience and develop cooperative studies.
ABMTRR promotes HSCT research and helps provide
access to and information about HSCT to people in Australia and New Zealand.
BMDW is a voluntary collaborative effort of stem cell
donor registries and cord blood banks whose goal is to
provide centralized information on the HLA phenotypes
and other relevant data of unrelated stem cell donors
and cord blood units and to make this information easily
accessible.
A Founding Member: CIBMTR collaborates with the
global scientific community to advance hematopoietic
cell transplantation and cellular therapy research
worldwide. A combined research program of the National Marrow Donor Program® and the Medical College
of Wisconsin, CIBMTR facilitates transplant outcome
research that has led to more than 800 peer-reviewed
publications. These publications have contributed to
increased survival and an enriched quality of life for
many transplant patients.
20
WBMT Annual Progress Report
Organization
Eastern Mediterranean Blood and
Marrow Transplantation (EMBMT)
www.embmt.org
Eurocord
www.eurocord-ed.org
European Federation for Immunogenetics (EFI)
www.efiweb.eu
European Group for Blood and
Marrow Transplantation (EBMT)
www.ebmt.org
European Leukemia Network (ELN)
http://www.leukemia-net.org
European Marrow Donor Information System (EMDIS)
www.emdis.net
European School of Haematology
(ESH)
www.esh.org
Foundation for the Accreditation of
Cellular Therapy (FACT)
www.factwebsite.org
Description
EMBMT promotes all aspects of patient care, academic,
and research activities associated with HSCT in eastern
Mediterranean countries with the goal of sharing experience, initiating cooperative trials, and establishing
common strategies to advance the field of HSCT.
Eurocord promotes national and international collaborations and disseminates HSCT knowledge. The Eurocord
registry operates on behalf of the EBMT, and Eurocord
works in close collaboration with Netcord cord blood
banks and EBMT centers and database.
EFI aims to promote research in immunogenetics, histocompatibility testing, and HSCT. It promotes the advancement of immunogenetics in Europe and supports
research and training in the field.
A Founding Member: EBMT aims to improve outcomes
of HSCT and provide information to the public about
developments in the field by sharing the experience of
European centers and encouraging cooperative research
among scientists and physicians in the HSCT field.
The European Leukemia Network is a research network
of 194 participating centers in 39 countries all cooperating in the Network The goal is a cure of leukemia by integration of European leukemia research. The website
delivers information (in various European languages) for
physicians, patients (e.g. patient organisations in Europe), ongoing clinical trials and further information
about leukemia.
The EMDIS system integrates the databases of European
blood and marrow donor registries allowing data exchange from and to heterogeneous systems and nationwide area networks.
ESH is a non-profit institution for continuing education
that promotes and facilitates access to research in hematology and related disciplines in Europe, North America, North Africa, and the Middle East. ESH also develops
tools for continuing education produced in collaboration
with international experts in the field.
FACT is a non-profit organization that establishes standards for high-quality medical and laboratory practices in
cellular therapies for the purposes of voluntary inspection.
21
WBMT Annual Progress Report
Organization
International Council for Commonality in Blood Banking Automation
(ICCBBA)
http://iccbba.org/
Description
ICCBBA is a not-for-profit, tax exempt, non-government
organization responsible for management of the ISBT
128 Information Standard for Blood and Transplantation,
a global standard for the terminology, identification,
labeling, and information transfer of human blood, cell,
tissue, and organ products across international borders
and disparate health care systems. It ensures the highest
levels of accuracy, safety, and efficiency for the benefit
of donors, patients, and ISBT 128 licensed facilities
worldwide. The system features a unique, highly flexible, and comprehensive coding method for every collected product and provides international consistency to
support the transfer, transfusion, or transplantation of
blood, cells, tissues and organs.
International Society of Blood
ISBT is an international professional society that faciliTransfusion (ISBT)
tates knowledge about transfusion and transplantation
www.isbtweb.org
science and medicine.
International Society of Cellular
ISCT is a global association that promotes cellular theraTherapy (ISCT)
pies research by fostering international translational
www.celltherapysociety.org
research, driving commercialization strategies, and
providing education.
Joint Accreditation Committee-ISCT JACIE is a non-profit organization that assesses and pro(Europe) & EBMT (JACIE)
vides accreditation in the field of HSCT. Its primary aim is
www.jacie.org
to promote high-quality patient care and laboratory performance in hematopoietic stem cell collection, processing and transplantation through an internationally
recognized system of accreditation. It partners with
EBMT, ISCT, and FACT.
Latin American Bone Marrow
The purpose of this group is to provide a mechanism
Transplantation group (LABMT)
through which Latin American Blood and Marrow Transwww.wbmt.org
plant and Hematology groups can collaborate and engage in scientific and educational activities and endeavours to promote excellence in stem cell transplantation,
stem cell donation, cellular therapy and hematologic
practices. Activities include data collection and sharing
outcome information.
Netcord
The International NetCord Foundation is a non-profit
www.netcord.org
association of umbilical cord blood banks whose members comprise the largest source of high-quality cord
blood grafts for patients in need of HSCT.
22
WBMT Annual Progress Report
Organization
World Marrow Donor Association
(WMDA)
www.worldmarrow.org
Description
A Founding Member: WMDA is a global association
whose mission is to assure that high-quality stem cell
products are available for all patients in need, while
maintaining the health and safety of the volunteer donors.
23
WBMT Annual Progress Report
APPENDIX B: EXECUTIVE COMMITTEE ELECTED OFFICERS
President
Yoshihisa Kodera, MD
Department of Promotion for Blood and
Marrow Transplantation
Aichi Medical University School of Medicine
1-1 Yazakokarimata, Nagakute
Aichi 480-1195 Japan
Tel: +81 561 62 3311 (Ext. 2375)
Fax: +81 561 61 3180
ykodera@river.ocn.ne.jp
Vice-President
Daniel Weisdorf, MD
Professor of Medicine
Director
Adult Blood & Marrow Transplant Program
University of Minnesota
MMC 480, Minneapolis, MN 55455 USA
Tel: +1 612 624 3101
Fax: +1 612 625 6919
weisd001@umn.edu
Immediate Past-President
Dietger Niederwieser, MD
Professor of Medicine, Dr. h. c.
Division of Hematology and Medical Oncology
Univ. of Leipzig, Johannisallee 32A
04103 Leipzig, Germany
Tel: +49 341 97-13050
Fax: +49 341 97-13059
dietger@medizin.uni-leipzig.de
24
WBMT Annual Progress Report
Treasurer
Dennis Confer, MD
Chief Medical Officer
3001 Broadway Street N. E. Suite 100
Minneapolis, MN 55413-1753
Tel: +1 612 362 3425
Fax: +1 612 845 0882
dconfer@nmdp.org
www.marrow.org
Secretariat
Hildegard Greinix, MD
I. Med. Univ. Klinik, KMT
Währinger Gürtel 18-20
A-1090 Wien
Austria
Tel: +43 1 40400 4402
Fax: +43 1 40400 5701
hildegard.greinix@meduniwien.ac.at
25
WBMT Annual Progress Report
APPENDIX C1: CENTER SITES THAT CONTRIBUTE DATA TO THE ACTIVITY SURVEY
26
WBMT Annual Progress Report
APPENDIX C2: COUNTRIES THAT HAVE CONTRIBUTED DATA
*Maximum number of teams
in any one survey year
2006-2012
WHO Region
Country
Number of Teams
EMR/AFR
Algeria
2
AMR/PAH
Argentina
22
SEAR/WPR
Australia
41
EUR
Austria
13
EUR
Azerbaijan
1
EUR
Belarus
2
EUR
Belgium
20
EUR
Bosnia and Herzegovina
2
AMR/PAH
Brazil
41
EUR
Bulgaria
2
AMR/PAH
Canada
26
AMR/PAH
Chile
5
SEAR/WPR
China
60
AMR/PAH
Colombia
4
AMR/PAH
Costa Rica
3
EUR
Croatia
3
EUR
Cyprus
2
EUR
Czech Republic
9
EUR
Denmark
4
EMR/AFR
Egypt
3
EUR
Estonia
2
EUR
Finland
7
EUR
France
74
EUR
Germany
109
EUR
Greece
12
SEAR/WPR
Hong Kong
3
EUR
Hungary
6
EUR
Iceland
1
SEAR/WPR
India
33
EMR/AFR
Iran
2
EUR
Ireland
6
27
WBMT Annual Progress Report
*Maximum number of teams
in any one survey year
2006-2012
WHO Region
Country
Number of Teams
EUR
Israel
9
EUR
Italy
98
SEAR/WPR
Japan
381
EMR/AFR
Jordan
1
EUR
Kazakhstan
1
EUR
Latvia
1
EMR/AFR
Lebanon
2
EUR
Lithuania
2
EUR
Luxembourg
1
EUR
Macedonia, FYR
1
SEAR/WPR
Malaysia
10
AMR/PAH
Mexico
7
EMR/AFR
Morocco
1
EUR
Netherlands
16
SEAR/WPR
New Zealand
6
EMR/AFR
Nigeria
1
EUR
Norway
6
EMR/AFR
Oman
1
EMR/AFR
Pakistan
3
AMR/PAH
Panama
3
AMR/PAH
Paraguay
1
AMR/PAH
Peru
1
SEAR/WPR
Philippines
1
EUR
Poland
18
EUR
Portugal
6
EUR
Romania
4
EUR
Russian Federation
14
EMR/AFR
Saudi Arabia
7
EUR
Serbia
4
SEAR/WPR
Singapore
5
EUR
Slovak Republic
5
EUR
Slovenia
1
EMR/AFR
South Africa
7
28
WBMT Annual Progress Report
*Maximum number of teams
in any one survey year
2006-2012
WHO Region
Country
Number of Teams
SEAR/WPR
South Korea
43
EUR
Spain
73
EUR
Sweden
8
EUR
Switzerland
9
SEAR/WPR
Taiwan
18
SEAR/WPR
Thailand
7
EMR/AFR
Tunisia
1
EUR
Turkey
46
EUR
Ukraine
2
EUR
United Kingdom
54
AMR/PAH
United States of America
191
AMR/PAH
Uruguay
5
AMR/PAH
Venezuela
2
SEAR/WPR
Vietnam
3
TOTAL
78 (77)
1607 (1533)
(……..) = previous year
29
WBMT Annual Progress Report
APPENDIX D: HISTORY OF BOARD MEETINGS
WBMT Board Business Meetings
WBMT Participant Meetings
2014
Teleconference (December)
Geneva (MPHO NGO meeting; September)
Teleconference (July)
Milan, Italy (March)
2013
Brasilia, Brazil (WBMT/NOFITY; December)
Teleconference (November)
Teleconference (July)
Geneva, Switzerland (WHO; May)
London, UK (Standing Committees; April)
Salt Lake City, UT, US (February)
2012
Atlanta, GA, USA (WBMT/LABMT; December)
Rome, Italy (WBMT/NOTIFY; November)
Teleconference (October)
Hyderabad, India (APBMT; October)
St. Petersburg, Russia (WBMT/Russia; September)
Lagos, Nigeria (WBMT/AFBMT; September)
Manila, Philippines (WBMT/Philippine Society of
Haematology; August)
Teleconference (June)
Geneva, Switzerland (April)
San Diego, CA, US (WBMT/LABMT; February)
2011
Teleconference (December)
Teleconference (September)
Rio de Janeiro, Brazil (SBTMO/LABMT; August)
Teleconference (June)
Teleconference (April)
Paris, France (Standing Committees; March)
Honolulu, HI, US* (February)
30
WBMT Annual Progress Report
WBMT Board Business Meetings
WBMT Participant Meetings
2010
Phuket, Thailand (APBMT; November)
Vienna, Austria (March)
Brussels, Belgium (WHO; February)
2009
Minneapolis, MN, US (November)
New York, NY, US (UN; October)
Nagoya, Japan (April)
Göteborg, Sweden (March)
2008
Minneapolis, MN, US (October)
Geneva, Switzerland (WHO; October)
Firenze/Florence, Italy (March)
Tampa, FL (February)
2007
Minneapolis, MN, US (October)
Lyon, France (March)
*1st elected Board meeting
31
WBMT Annual Progress Report
APPENDIX E: HISTORY OF INTERNATIONAL SCIENTIFIC SYMPOSIA
2014
April, EBMT Meetings (Milan)
Hematopoietic Stem Cell Trasnplantation: Access and Affordability
Co-Chairs: D. Niederwieser, MD; Y. Kodera, MD; D. Confer, MD; D. Wiesdorf, MD; H. Greinix,
MD
 Non-Government Organization (NGO): Status significance and opportunities of NGO (J.
Nunez)
 Cost of non-transplant therapy for hematologic malignancies (J. Apperley)
 Alternative donor selection:
o Haploidentical donor (L. Luznik)
o Cord blood stem cell transplantation (M. Eapen)
February, BMT Tandem Meetings (Dallas)
Hematopoietic Stem Cell Trasnplantation: Access and Affordability
Co-Chairs: D. Niederwieser, MD; Y. Kodera, MD; D. Confer, MD; D. Wiesdorf, MD; H. Greinix,
MD
 Non-Government Organization (NGO): Status significance and opportunities of NGO (J.
Nunez)
 Cost of non-transplant therapy for hematologic malignancies (J. Apperley)
 Alternative donor selection:
o Haploidentical donor (X-J. Huang)
o Cord blood stem cell transplantation (D. Wiesdorf)
2013
April, EBMT Meetings
The Legacy of E. Donnall Thomas: One Million Hematopoietic Stem Cell Transplants
Co-Chairs: D. Niederwieser, MD; Y. Kodera, MD; D. Confer, MD; H. Greinix, M.D.
 E. Donnall Thomas: From Cooperstown to Global (R. Storb)
 Challenges to Future Growth: The Transplant Center Perspective
o Europe (M. Mohty)
o Eastern Mediterranean (M. Aljurf)
o Africa (N. Novitzky)
 Challenges to Future Growth: The Donor Registry Perspective (D. Confer)
 Challenges to Future Growth: The WHO Perspective (L. Noël)
 Improving Research Collaborations to Move Forward (M. Horowitz)
32
WBMT Annual Progress Report
February, BMT Tandem Meetings
The Legacy of E. Donnall Thomas: 1 Million Hematopoietic Stem Cell Transplants
Co-Chairs: D. Niederwieser, MD; Y. Kodera, MD; D. Confer, MD; H. Greinix, MD
 E. Donnall Thomas: From Cooperstown to Global (F. Appelbaum)
 Challenges to Future Growth: The Transplant Center Perspective
o North America (R. Champlin)
o Central/South America (C. Bonfim)
o Asia-Pacific (A. Srivastava)
 Challenges to Future Growth: The Donor Registry Perspective (D. Confer)
 Challenges to Future Growth: The WHO Perspective (L. Noël)
 Improving Research Collaborations to Move Forward (J. Apperley)
2012
WBMT Scientific Session
Chair: D. Niederwieser, MD
 WBMT Update (D. Niederwieser)
 The Macroeconomics of Hematopoietic Stem Cell Transplantation (A. Gratwohl)
 A Global View of Cord Blood Transplantation (V. Rocha)
 The Fukushima Nuclear Accident – The Transplant Team Experience (S. Taniguchi)
2011
WHO and WBMT: A Model for Optimal Collaboration Between Scientists and Health Institutions
Co-Chairs: D. Confer, MD; Y. Kodera, MD; and D. Niederwieser, MD
 Update on WBMT Activity (D. Niederwieser)
 Global HSCT Activity Survey 2007-2008 (H. Baldomero)
 Report from the APBMT Congress: HSCT Activity and Plans for a Vietnam Meeting (Y.
Kodera)
 Harmonizing Standards in BMT – Improving Outcomes on a Global Scale (K. Loper)
 WHO and WBMT a Model for Optimal Collaboration Between Scientists and Health
Institutions (L. Noël)
2010
Worldwide Network for Blood and Marrow Transplantation (WBMT) Session
Chairs: D. Niederwieser, MD and M. Horowitz, MD, MS
 Update on Progress of WBMT (D. Niederwieser)
 Challenges in Establishing HSCT Outcomes Registries in Developing Countries AsiaPacific BMT Group (Y. Atsuta)
 Eastern Mediterranean BMT Group (M. Aljurf)
 Ethical Issues in Donation of Hematopoietic Stem Cells (A. Capron)
33
WBMT Annual Progress Report
2009
WBMT International Session (Supported by THERAKOS, Inc.)
Co-Chairs: D. Niederwieser, MD; S. Davies, MD; Y. Kodera, MD; and M. Oudshoorn, PhD
 Overview of Unrelated Adult and Cord Blood Donation: the WMDA Annual Survey (M.
Oudshoorn)
 Unrelated Donor Outcomes and Plans for Assessing Related Donor Outcomes: A Report
from the NMDP/CIBMTR (D. Confer)
 Related Donor Outcomes from the Japanese Registry: The Importance of Preregistration (Y. Kodera)
 Proposal for an EBMT Donor Outcome Registry (J. Halter)
34
APPENDIX F: PUBLICATIONS LIST Author(s) Title Citation Credited to: Submitted in 2014 – remains under consideration Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, Gratwohl M, Bouzas F, Confer D, Frauendorfer K, Gluckman E, Greinix H, Horowitz M, Iida M, Lipton J, Madrigal A, Mohty M, Noel L, Novitzky N, Nunez J, Oudshoorn M, Passweg J, van Rood J, Szer J, Blume K*, Appelbaum F, Kodera Y, Niederwieser D, for the Worldwide Network of Blood and Marrow Transplantation WBMT Worel N, Buser A, Greinix H T, Hägglund, H, Navarro W, Pulsipher A A, Nicoloso de Faveri G, Bengtsson M, Billen A, Espino G, Fechter M, Giudice V, Hölig K, Kanamori H, Kodera Y, Netelenbos T, Niederwieser D, van Walraven S M, Rocha V, Vergueiro C, Weisdorf D, Yabe H, Halter J P Hematopoietic stem cells: lessons from the journey to one million transplants Suitability criteria for related donors with disorders affecting the immune or endocrine system, metabolism, skin, musculoskeletal, neurologic and psychiatric health, and woman health issues: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT) standing committee on donor issues (part III) Worel N, Buser A, Greinix H T, Hägglund, Suitability criteria for related donors with H, Navarro W, Pulsipher A A, Nicoloso de disorders of the lung, gastro‐ intestine, Faveri G, Bengtsson M, Billen A, Espino G, liver, spleen, biliary tract, pancreas, kidney, Fechter M, Giudice V, Hölig K, Kanamori H, genitourinary tract, heart, vascular system, eye, blood and malignancies: A consensus Kodera Y, Netelenbos T, Niederwieser D, van Walraven S M, Rocha V, Vergueiro C, statement from the Worldwide Network for Weisdorf D, Yabe H, Halter J P Blood and Marrow Transplantation (WBMT) standing committee on Donor Issues (part ll) 35 Submitted to The Lancet Haematology (Reference number: THELANCETHAEMATOLOGY‐D‐14‐
00101R1) WBMT Submitted to Bone Marrow Transplantation (Reference number: BMT‐2014‐1062) WBMT Donor Issues Standing Committee Submitted to Bone Marrow Transplantation (Reference number: BMT‐2014‐1055) WBMT Donor Issues Standing Committee Author(s) Worel N, Buser A, Greinix H T, Hägglund, H, Navarro W, Pulsipher A A, Nicoloso de Faveri G, Bengtsson M, Billen A, Espino G, Fechter M, Giudice V, Hölig K, Kanamori H, Kodera Y, Netelenbos T, Niederwieser D, van Walraven S M, Rocha V, Vergueiro C, Weisdorf D, Yabe H, Halter J P Title Citation General considerations for related stem cell Submitted to Bone Marrow Transplantation (Reference number donors: A consensus statement from the Worldwide Network for Blood and Marrow BMT‐2014‐1054) Transplantation (WBMT) standing committee on Donor Issues. (part I) Credited to: WBMT Donor Issues Standing Committee Published in 2014 Celluzzi CM, Keever‐Taylor C, Alurf M, Koh K, Rabe F, Rebulla P, Sacchi N, Sanders J, McGrath E, Loper, K on behalf of The Alliance for Harmonisation of Cellular Therapy Accreditation (AHCTA) Aljurf M, Rizzo J D, Mohty M, Hussain F, Madrigal A, Pasquini MC, Passweg J, Chaudhri N, Ghavamzadeh A, El Solh H, Atsuta Y, Szer J, Kodera Y, Niederweiser D, Gratwohl A, Horowitz MM Leemhuis T, Padley D, Keever‐Taylor C, Niederwieser D, Teshima T, Lanza F, Chabannon C, Szabolcs P, Bazarbachi A, Koh, M Training Practices of HPC(A) and HPC(CB) Collection Staff: Analysis of a Survey by the Alliance for Harmonisation of Cellular Therapy Accreditation Challenges and Opportunities for HSCT Outcome Registries; Perspective from International HSCT Registries Experts Minimal Requirements and Essential Features for Setting up a Stem Cell Processing Laboratory Transfusion (2014) Vol 54, Issue 12, 3138‐3144 ;[Epub 2014 May] WBMT Regulation and Accreditation Committee (AHCTA) Bone Marrow Transplantation (2014), WBMT 1–6 [Epub 2014 April 28] Transplant Center and Recipient Committee Bone Marrow Transplantation (2014) WBMT Graft 49, 1098–1105; [Epub 2014 June 16] Processing Committee Published in 2013 Niederwieser D for the Worldwide Network for Blood and Marrow Transplantation One Millionth Blood Stem Cell Transplant Rev Hematol Mex 2013;14:84‐85 Marks Major Medical Milestone: International Cooperation Among Physicians, Scientists Credited for Landmark Achievement 36 WBMT Author(s) Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas L, Horowitz M, Kodera Y, Lipton J, Iida M, Pasquini M, Passweg J, Szer J, Madrigal A, Frauendorfer K, Niederwieser D Halter JP, van Walraven SM, Worel N, Bengtsson M, Hägglund H, Nicoloso de Faveri G, Shaw BE, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, Horowitz MM, Greinix H, Niederwieser D, Gratwohl A, Kodera Y, Confer D Title Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT) Citation Haematologica. 2013 Aug;98(8):1282‐
90. doi: 10.3324/haematol.2012.076349. [Epub 2013 Mar 18] Credited to: WBMT Bone Marrow Transplant. 2013 48, 220–225; doi:10.1038/bmt.2012.119; [Epub 2012 July 09]. WBMT Donor Safety Committee JAMA. 2010; 303(16):1617‐1624. doi:10.1001/jama.2010.491. WBMT Haematologica 2009; 94:94‐101. doi: 10.3324/haematol.13668 WBMT Donor Safety Committee Published in 2010 Gratwohl G, Baldomero H, Aljurf M, Hematopoietic stem cell transplantation; a Pasquini M, Bouzas L, Yoshimi A, Szer J, global perspective Lipton L, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, Horowitz M, Kodera Y, for the Worldwide Network of Blood and Marrow Transplantation Published in 2009 Halter J, Kodera Y, Urbano Ispizua A, Severe events in donors after allogeneic Greinix HT, Schmitz N, Favre G, Baldomero hematopoietic stem cell donation. H, Niederwieser D, Apperley JF, and Gratwohl A, for the European Group for Blood and Marrow Transplantation (EBMT) activity survey office 37 WBMT Annual Progress Report
APPENDIX G: TERMS AND ABBREVIATIONS
Term /
Abbreviation
AABB
ABMTRR
AFBMT
AHCTA
APBMT
ASBMT
ASH
BIG V&S SARE
BM
BMDW
CB
CIBMTR
CME
CNT
EBMT
EDQM
EHA
ELN
ESH
FACT
GODT
FAQs
GTCN
HPC
HSCT
ICCBBA
ISBT
ISCT
LABMT
MCI
MPHO
NGO
NIHBT
NMDP
ONT
Definition
AABB; formerly known as American Association of Blood Banks
Australasian Bone Marrow Transplant Recipient Registry
African Blood and Marrow Transplant Group
Alliance for the Harmonization of Cellular Therapy Accreditation
Asia-Pacific Blood and Marrow Transplantation Group
American Society for Blood and Marrow Transplantation
American Society of Hematology
Bologna Initiative for Global Vigilance and Surveillance of Adverse Reactions
and Events
bone marrow
Bone Marrow Donors Worldwide
cord blood
Center for International Blood and Marrow Transplant Research
continuing medical education
Italian National Transplant Centre
European Blood and Marrow Transplantation Group
European Directorate for the Quality of Medicines & HealthCare
European Hematology Association
European Leukemia Network
European School of Haematology
Foundation for Accreditation of Cellular Therapy
Global Observatory on Donation and Transplantation
Frequently Asked Questions
global transplant center number
human progenitor cells
hematopoietic stem cell transplantation
International Council for Commonality in Blood Banking Automation
International Society of Blood Transfusion
International Society of Cellular Therapy
Latin American Blood and Marrow Transplant Society
MCI Suisse SA, a professional congress organizer
medical products of human origin
Non-government Organization
National Institute of Hematology and Bone Marrow Transplantation
National Marrow Donor Program
Organización Nacional de Transplantes
38
WBMT Annual Progress Report
Term /
Abbreviation
PB
PBSC
RITN
SBMTO
SOHO V&S
TAS
UN
WBMT
WHO
WMDA
Definition
peripheral blood
peripheral blood stem cells
Radiation Injury Treatment Network
Sociedade Brasileira de Transplante de Medula Óssea
Vigilance and Surveillance of Substances of Human Origin
Transplant Activity Survey
United Nations
Worldwide Network for Blood and Marrow Transplantation
World Health Organization
World Marrow Donor Association
39